Intersect ENT, Inc. (XENT) Financial Analysis & Valuation | Quarter Chart
Intersect ENT, Inc. (XENT)
XENTPrice: $28.24
Fair Value: 🔒
🔒score
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the United States. The company offers PROPEL, a steroid releasing implant to open the surgically enlarged sinus; PROPEL Mini, a releasing implant to treat patients undergoing frontal sinus surgery; and PROPE... more
Intersect ENT, Inc. operates as an ear, nose, and throat (ENT) medical technology company in the Uni... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Medical - Devices |
| Country | US | CEO | Thomas West |
| IPO Date | 2014-07-24 | CAGR | 0.38% |
| Employees | 433 | Website | www.intersectent.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
XENT chart loading...
Fundamentals
Technicals
| Enterprise Value | $1.08B | P/E Ratio | -10.54 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | -13.6 |
| P/CF Ratio | -15.8 | P/FCF Ratio | — |
| EPS | $-2.68 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 22.27% | Gross Margin | 0.72% |
| Operating Margin | -1.45% | Profit Margin | -1.5% |
| ROE | 155.21% | ROA | -1.09% |
| ROCE | -1.73% | Current Ratio | 1.85 |
| Quick Ratio | 1.53 | Cash Ratio | 0.67 |
| Debt/Equity | -2.06 | Interest Coverage | -24.06 |
| Altman Z Score | — | Piotroski Score | — |